Chelsea and Westminster Hospital
NHS Foundation Trust

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Group

Summary of Main Points from the Meeting held on Monday 10th February 2025

2. Minutes and Summary Notes from last meeting

This meeting was held via Teams. The Minutes and Summary notes of the Medicines Group Meeting held on 11th November 2024 were approved. The summary notes will be disseminated and published on the Trust intranet. A quarterly summary report will be drafted and forwarded to the Trust Patient Safety Group meeting for inclusion on the agenda in due course.

3. Matters Arising

The Group noted the matters arising from the previous meeting.

4. Business to be transacted by the Medicines Group

4.1 Formulary Applications

Full Applications

- Nil

Short Applications

- **Ocrelizumab (Ocrevus®) 920mg SC Injection**

Requested by: Neurology
Proposal: Add Ocrelizumab (Ocrevus®) to the formulary as a SC injection formulation.
IV formulation is already included on the Trust Formulary.
The SC injection formulation will allow patients the option to have Ocrelizumab (Ocrevus®) administered via Homecare. This formulation will be prescribed as per NHSE MS treatment algorithm.
Outcome: Approved for addition to the Trust Formulary

- **Amphoteracin B (Liposomal) 50mg Injection (Generic switch)**

Requested by: Microbiology
Proposal: Add new liposomal amphotericin B product (Tillomed brand) to the Trust Formulary as a generic equivalent to the Gilead product (Ambisome brand) currently used. Both products have similar product licensing and dosing. This is a more cost-effective option for treating suspected or confirmed invasive fungal infections.
Outcome: Approved for addition to the Trust Formulary

- **Botulinum Toxin (Dysport®) 300units Injection**

Requested by: Surgery
Proposal: Add Botulinum Toxin (Dysport®) 300 units on the Trust Formulary to allow supply to the nearest vial size and minimise wastage.
Botulinum Toxin (Dysport®) 500 units is currently included on the Trust Formulary.
Cost per unit identical but cost saving will be realised in the reduction of wasted part used vials.
Outcome: Approved for addition to the Trust Formulary

- **Cholecalciferol (InVita D3®) 50,000unit Capsules**

Requested by: Medicine
NWL ICB Management of Vitamin D deficiency in Adults Guideline (Approved in Oct 2024) recommends the following treatment dose for rapid correction of vitamin D deficiency:

- Prescribe a total loading dose of approximately 300,000 units of vitamin D over a 6-week period.
- 50,000units once a week for 6 weeks is one of the recommended licensed treatment doses for Cholecalciferol (InVita D3®) 50,000unit Capsules.

Proposal: Add Cholecalciferol (InVita D3®) 50,000unit Capsules to the formulary to support treatment under this guideline.
Currently included on the NWL ICB JF
Outcome: Approved for addition to the Trust Formulary

- **Budesonide 4mg Suppositories**

Requested by: Gastroenterology
Proposal: Add Budesonide Suppositories to replace prednisolone suppositories as the first line agent on account of
  - Similar clinical efficacy
  - Price has increased significantly over recent years.

Budesonide = £198+ VAT = £237 for 30 days
Prednisolone = £251 + VAT for 10 = £903 for 30 days
Added to the NWL ICB JF in January 2025.
Outcome: Approved for addition to the Trust Formulary

- **Thiamine 250mg Injection**

Requested by: Medicine
Pabrinex is currently out of stock nationally from July 2024 to September 2025 due to supply issues relating to manufacturing regulations issued by EU.
Proposal: Add Thiamine Injection to the formulary as an alternative treatment option.
Outcome: Approved for addition to the Trust Formulary

- **Taurolock (Taurolidine/Urokinase) 25,000unit Injection**

Requested by: Medicine
There are currently long standing stock shortage of Urokinase nationally.
Proposal: Add Taurolock (Taurolidine/Urokinase 25,000 unit) Injection to the formulary as an alternative treatment option.
Outcome: Approved for addition to the Trust Formulary

- **Naldemedine 200microgram Tablets**

Requested by: Gastroenterology
Licensed use: Opioid-induced constipation in adult patients who have previously been treated with a laxative.
There are currently long standing stock shortage of Nalaxogel nationally.
Proposal: Add Naldemedine 200microgram Tablets to formulary for use in opioid-induced constipation in place of Naloxogel
Currently included on the NWL ICB JF
Outcome: Approved for addition to the Trust Formulary

NICE TA Applications

- **TA1005 Futibatinib for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (11/09/2024)**

Proposal: Add to the formulary in line with NICE TA1005
Outcome: Approved for addition to the Trust Formulary

- **TA1009 Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension (02/10/2024)**

Proposal: Add to the formulary in line with NICE TA1009
Outcome: Approved for addition to the Trust Formulary

- **TA1012 - Avapritinib (Ayvakyt) for treating advanced systemic mastocytosis (06/11/2024)**

Proposal: Add to the formulary in line with NICE TA1012
Outcome: Approved for addition to the Trust Formulary

- **TA1015 - Teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments (13/11/2024)**

Proposal: Add to the formulary in line with NICE TA1015
Outcome: Approved for addition to the Trust Formulary

- **TA1023 - Elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments (11/12/2024)**

Proposal: Add to the formulary in line with NICE TA1023
Outcome: Approved for addition to the Trust Formulary

- **TA1025 - Ublituximab (Briumvi) for treating relapsing multiple sclerosis (18/12/2024)**

Proposal: Add to the formulary in line with NICE TA1025
Outcome: Approved for addition to the Trust Formulary

NWL ICB JFC Applications

- **Fobumix (Budesonide/Formoterol) Easyhaler®**
  - **80 micrograms/4.5micrograms, Inhalation Powder**
  - **160 micrograms/4.5micrograms, Inhalation Powder**
  - **320 micrograms/9micrograms, Inhalation Powder**

Proposal: Add all three formulations to the formulary in line with NWL ICB JFC decision
Outcome: Approved for addition to the Trust Formulary

- **Trimbow® Beclometasone dipropionate 172microgram/Formoterol fumarate dihydrate 5microgram/Glycopyrronium bromide 9microgram Nexthaler (Dry Power Inhaler)**

Proposal: Lower strength formulation currently included on the formulary.
Add higher strength to the formulary in line with NWL ICB JFC decision.
Outcome: Approved for addition to the Trust Formulary

Pharmacoeconomic Board Applications

- **Infliximab for Crohns's Disease**

Approved by Pharmacoeconomic Board on 30/11/2024
Outcome: Noted

- **Ritixumab for AQP4 positive NMOSD**

Approved by Pharmacoeconomic Board on 11/12/2024
Outcome: Noted

- **Glofatimab for high grade B-cell lymphoma**

Approved by Pharmacoeconomic Board on 18/12/2024
Outcome: Noted

- **Delafloxacin for Mycoplasma Genitalium**

Approved by Pharmacoeconomic Board on 14/01/2025
Outcome: Noted

- **Ranibuzumab for Wet AMD**

Approved by Pharmacoeconomic Board on 22/01/2025
Outcome: Noted

- **Dupilumab for Eosinophilic Gastroenteritis (Additional paper)**

Approved by Pharmacoeconomic Board on 10/02/2025
Outcome: Noted

Removals

- **Acetazolamide 250mg MR Capsules**

Proposal: Remove from the formulary. Discontinued by the manufacturer
Outcome: Approved for removal from the Trust Formulary

- **Levobunolol 0.5% Eye drops**

Proposal: Remove from the formulary. Discontinued by the manufacturer
Outcome: Approved for removal from the Trust Formulary

- **NovoRapid (Insulin Aspart) FlexTouch 100unit/ml Pre-filled pen**

Proposal: Remove from the formulary. Discontinued by the manufacturer
Outcome: Approved for removal from the Trust Formulary

- **Sodium Fusidate 250mg Tablets**

Proposal: Remove from the formulary. Discontinued by the manufacturer
Outcome: Approved for removal from the Trust Formulary

4.2 Trust Medicines Policy

- **TMP: Section 30 - Supply of Over-labelled/Pre-packed medicines**

Addition of the following as a clinical areas at WMUH that can operate in line with this policy:
- Lampton Ward

Outcome: Approved

- **TMP: Section 4 - Storage of medicines**

Addition of:
- RPSGB standards in an audit form in Appendix 4.6
- Statement: If a drug storage space used for the storage of medicines is labelled, an A-Z labelling system should be used in preference to using specific medicine names.
- Statement: Patient's own medicines that have been left on the hospital premises cannot be returned into Pharmacy/ward stock and/or reused irrespective of storage and/or expiry date and must be discarded.
- Need to store intravenous fluids and frequently used small volume injections presented in vials/ampoules in their original packaging, not loose, or decanted unless there is a risk assessment in place.
- Additional section relating to insulin: Annotation of expiry date on insulin vials once opened; Labelling of pre-filled insulin pens with patient's name and expiry date.
- Annotation of medicines that have limited shelf life on opening with the allocated expiry date once opened.
- Clarity that temperature reading should be taken *at least once* every 24 hours.
- Action to take relating to temperature monitoring if a clinical area is temporary closed.
- Statement: There is a minimum of one ambient thermometer in place on the ward/department which is located in the Treatment Room, if there is one present, or in the area where the majority of the stock medicines are stored.
- Use of an electronic solution (e.g. FDP) to record ambient temperatures.
- Safe and secure storage of medicines on wards/departments Audit Form in Appendix 4.7.

Update of:
- Appendix 4.1

Outcome: Approved pending approval by Head of Nursing

TMP: Section 5 - Transport of medicines

Routine review and update
- Update of title
- Addition of hospital volunteers being permitted to delivery medicines from Pharmacy to wards/departments.
- Use of Webtracker for electronically ordering controlled drugs.
- Cut-off time of 11am for receipt of electronic orders for CDs to be dispensed on the same day.
- Update to the collection of CDs from Pharmacy in light of introduction of electronic CD ordering.
- Removal of colour descriptors for Pharmacy delivery bags.

Outcome: Approved

- **TMP: Section 13 - Medicines related incidents**

Routine review and update of policy

- Need to complete a Trust incident report on Datix relating to any medicines-related incident identified as being suspected of causing moderate harm. Level of harm to be agreed with the responsible consultant.

Outcome: Approved

- **TMP: Section 21 - Patient Group Directions**

Routine review and update

Update of:

- Trust PGD Lead
- PGD proforma

Addition of:

- Pharmacy Technicians permitted to work under PGD
- Section relating to determining need for PGD
- Section relating to expectation and responsibility for cross-site PGDs
- Section relating to the supply of information leaflets to patients treated under PGD.
- Section relating to National approved PGDs
- Appendix 21.2 - National approved PGD - Front sheet
- Responsibility for follow-up of expiring PGDs changed from the Pharmacy PGD Lead to the relevant Divisional Nurse

Outcome: Approved

4.3 Medicines Optimisation

- **Supply of unlicensed Human Varicella Zoster Immunoglobulin (Varitect CP) by the UKHSA directly to requesting clinician - Risk Assessment**

The Trust Unlicensed Medicines Policy states that all unlicensed medicines must be ordered and received through the pharmacy department and sent for Quality Assurance approval by the Quality Assurance team at Imperial Collage Healthcare NHS Trust before being supplied to patients.

Due to the discontinuation of UK licenced Human Varicella Zoster Immunoglobulin the UKHSA are now supplying Varitect CP brand - licenced in Germany - but not licenced in the UK.

Varitect CP is supplied from the UKHSA in response to an individual patient request by a clinician. This is usually supplied directly to the ward to expedite administration. Therefore, this unlicensed medicine will not undergo the quality assurance process stipulated in Trust Policy.

Outcome: Approved

4.4 NICE Technical Appraisals and Guidance

18 TA appraisals published since previous TMG meeting to February 2025

- **TA1010 Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (23/10/2024)**

Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1011 Belzutifan for treating tumours associated with von Hippel-Lindau disease (16/10/2024)**

Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1012 Avapritinib for treating advanced systemic mastocytosis (06/11/2024)**

Formulary status / Action
Not included on the formulary

Application form received - See Section 4.1

- **TA1013 Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (23/10/2024)**

Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1014 Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer (13/11/2024)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 1 patient per year

- **TA1015 Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (13/11/2024)**

Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

- **TA1016 Elafibranor for previously treated primary biliary cholangitis (14/11/2024)**

Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Only allowed to be prescribed by Hepatology ODN Hub sites

- **TA1017 Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer (20/11/2024)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 2-3 patients per year
Numbers likely to treat at WMUH site: 2-3 patients per year

- **TA1018 Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (20/11/2024)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1-2 patients per year
Numbers likely to treat at WMUH site: 2-4 patients per year

- **TA1019 Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (20/11/2024)**

Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1020 Eplontersen for treating hereditary transthyretin-related amyloidosis (27/11/2024)**

Formulary status / Action
Not included on the formulary
Action: Not applicable to CWFT - Condition not treated at CWH and WMUH site

- **TA1021 Crizotinib for treating ROS1-Positive advanced NSCL (04/12/2024)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: 1 patient per year
Numbers likely to treat at WMUH site: 1 patient per year

- **TA1022 Bevacizumab gamma for treating wet age-related macular degeneration (04/12/2024)**

Formulary status / Action
Not included on the formulary

Application form received - See Section 4.1

- **TA1023 Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (11/12/2024)**

Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

- **TA1024 Toripalimab with chemotherapy for untreated advanced oesophageal squamous cell cancer (terminated appraisal) (11/12/2024)**

Formulary status / Action
Nil - Terminated Appraisal

- **TA1025 Ublituximab for treating relapsing multiple sclerosis (18/12/2024)**

Formulary status / Action
Not included on the formulary
Application form received - See Section 4.1

- **TA1026 Tirzepatide for managing overweight and obesity (23/12/2024)**

Formulary status / Action
Included on the formulary for another indication
Numbers likely to treat at CWH site: __ patients per year - To be confirmed
Numbers likely to treat at WMUH site: 0 patient per year

- **TA1027 Tebentafusp for treating advanced uveal melanoma (09/01/2025)**

Formulary status / Action
Not included on the formulary
Action: Nil - Not applicable to CWFT
(Human specific protein that requires specialist preparation - Patents likely to be referred to unit that has more frequent use)

b) NICE Highly Specialised Technology Appraisals published since last meeting

0 HST appraisal published since previous TMG meeting to February 2025
Action: Nil - Not applicable to CWFT

4.5 Items for noting

- **Quarterly Controlled Drug Summary Report - Q2 2024/25**

Quarterly Controlled Drug Summary Report for Q2 2024/25
Outcome: Noted

- **Quarterly Controlled Drugs Accountable Officer Report - Q2 2024/25**

Quarterly CD Accountable Officer Report for Q2 2024/25
Outcome: Noted

- **Medication Safety Bulletin: Insulin Safety on Discharge**

Medication Safety Bulletin relating to Insulin Safety on Discharge
Outcome: Noted

- **Medication Safety Bulletin: Antimicrobials: Intravenous-to-Oral (IV-PO) switch**

Medication Safety Bulletin relating to Antimicrobials: Intravenous-to-Oral (IV-PO) switch
Outcome: Noted

- **Medication Safety Bulletin: Summary of Medication-Related Incidents in 2024**

Medication Safety Bulletin relating Summary of Medication-Related Incidents in 2024
Outcome: Noted

- **MHRA Drug Safety Update - November 2024**

MHRA update for November 2024
Outcome: Noted

- **MHRA Drug Safety Update - December 2024**

MHRA update for December 2024
Outcome: Noted

- **MHRA Drug Safety Update - January 2025**

MHRA update for January 2025
Outcome: Noted

4.6 Meeting minutes for noting

- **Trust Medicines Safety Group - Terms of Reference 2024**

Trust Medicines Safety Group - Terms of Reference 2024
Outcome: Approved

- **Trust Medicines Optimisation Steering Group - Terms of Reference 2024**

Trust Medicines Optimisation Group - Terms of Reference 2024
Outcome: Approved

- **Trust Chemotherapy Services Group - Terms of Reference 2024**

Trust Medicines Chemotherapy Services Group - Terms of Reference 2024
Outcome: Approved

- **Trust Medicines Optimisation Steering Group - Action Log**

Trust Medicines Optimisation Group - Action Log - Date 2024
Outcome: Noted

- **Trust Medicines Safety Group - Meeting Minutes - October 2024**

Trust Medicines Safety Group - Meeting Minutes - October 2024
Outcome: Noted

- **Trust Medicines Safety Group - Meeting Minutes – December 2024**

Trust Medicines Safety Group - Meeting Minutes - December 2024
Outcome: Noted

- **NWL ICB Joint Formulary Committee Meeting Minutes - September 2024**

Minutes from NWL ICB Joint Formulary Committee Meeting held September 2024
Outcome: Noted

5. Any other business
Nil

6. Date of next meeting
Meetings Dates for 2025

Date:

- **16th May 2025**
- **29th September 2025**
- **24th November 2025**

Time: 8am-9am
Location: via Teams